In a groundbreaking advancement poised to reshape our understanding of biological aging, researchers from Fudan University have unveiled an innovative method for the absolute quantification of aging-associated glycans on immunoglobulin G (IgG). This pioneering approach not only offers a highly precise biological age prediction model but also opens a promising pathway for anti-aging therapeutic development. Published recently in the journal Engineering, the study marks a significant leap by integrating detailed glycomic and transcriptomic analyses to illuminate the molecular dynamics underpinning age-related alterations in IgG N-glycans.
Central to this research is the comprehensive longitudinal profiling of IgG N-glycans conducted on C57BL/6 mice, evaluated at seven critical time points spanning an 80-week lifecycle. Utilizing matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), the team detected subtle, yet consistent, shifts in glycan structures. These alterations were quantified not just relatively—common in prior studies—but through an unprecedented absolute concentration strategy facilitated by external glycan standards. By implementing this refined analytical technique, the researchers quantified precise amounts of key glycans signaling biological aging, overcoming longstanding challenges in glycomic biomarker reproducibility.
The data revealed two glycans with particularly robust associations to aging: the bisected glycan GP3 (F(6)A2B), which experienced significant downregulation, and the digalactosylated glycan GP8 (F(6)A2G2), whose levels steadily increased from early adulthood onward. Leveraging these findings, the research team developed the abGlycoAge index—a novel predictive model that translates absolute concentrations of these glycans into a biologically relevant age metric. This precise quantification advances the field beyond prior relative abundance metrics, offering a more stable and translatable measurement of biological aging that could, ultimately, be applicable across species or in clinical settings.
To validate the biological relevance and functional implications of the abGlycoAge model, the study incorporated caloric restriction (CR) experiments, a well-established intervention known to extend lifespan and modulate biological aging markers. Analysis of CR-fed mice demonstrated that the abGlycoAge index effectively reflected a younger biological state, capturing an age reduction ranging from approximately 3.9 to 14.0 weeks compared to ad libitum-fed counterparts. This validation is critically important, showcasing the model’s sensitivity to anti-aging interventions and bolstering confidence in its utility for assessing the efficacy of such treatments in real time.
Delving deeper into the molecular drivers behind these glycan changes, the researchers performed comprehensive RNA sequencing analyses on splenic B cells, the key cellular source of IgG. This high-resolution transcriptomic investigation uncovered differential expression patterns in genes including Derl3, Smarcb1, Ankrd55, Tbkbp1, and Slc38a10, whose regulation appeared to correlate with aging. Intriguingly, caloric restriction partially reversed the expression shifts of these genes, underscoring their potential role in modulating glycosylation pathways during aging. Importantly, subsequent gene set enrichment analyses highlighted significant perturbations in protein N-linked glycosylation pathways in aged animals, concordant with the glycomic observations.
Moving from biomarker identification to therapeutic experimentation, the study explored glycoengineering as an intervention. Aged mice (80 weeks old) were administered IgG immunoglobulins modified to carry youthful N-glycan signatures, termed IgG-Ny. Remarkably, mice treated with high-dose IgG-Ny showed robust alleviation of several hallmarks of aging, including reductions in pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha levels. Additionally, markers of cellular senescence, such as senescence-associated β-galactosidase activity, were substantially diminished across critical organs including the brain, kidneys, and lungs. Lower dosing yielded less consistent outcomes, suggesting dose-dependent and tissue-specific therapeutic responses.
This dual approach of combining absolute glycan quantification with transcriptomic profiling charts a new course for biological age prediction while highlighting the molecular intricacies governing IgG glycosylation changes. The abGlycoAge model, anchored by stable glycan biomarkers GP3 and GP8, lays a strong foundation for future research avenues aiming to develop personalized aging diagnostics and targeted interventions. Moreover, the encouraging therapeutic findings emphasize the untapped potential of glycoengineered IgG molecules as modulators of age-associated inflammatory and senescence pathways, offering hope for mitigating physiological decline.
Beyond academic novelty, this study’s methodological leap underscores a broader trend in biogerontology: the migration from relative to absolute quantification of molecular aging signatures. Such precision is crucial to the translation of glycomic biomarkers into clinical practice, where reproducibility, sensitivity, and standardized units are paramount. By anchoring measurements to exogenous standards that ensure exact glycan concentration readings, this research addresses a fundamental limitation in biomarker science and positions glycan profiling as a practical tool in aging medicine.
The implications of this work resonate strongly given that IgG constitutes a central player in immune regulation, pathogen defense, and inflammatory modulation. Age-related glycosylation shifts in IgG have been historically linked with immune dysfunction and chronic inflammation, hallmarks of aging associated with multiple morbidities. Thus, the ability to precisely quantify these modifications and intervene through glycoengineered antibodies could revolutionize how aging and related diseases are diagnosed and treated.
Looking ahead, this study beckons further exploration into the mechanistic pathways by which identified genes orchestrate glycan synthesis and remodeling during aging. Additionally, extending these findings into human cohorts and diverse therapeutic contexts will be crucial to validate and broaden the translational impact. The prospect of routinely tracking biological age through minimally invasive blood tests measuring absolute IgG glycan concentrations could transform preventive health strategies, enabling early interventions tailored to an individual’s molecular aging profile.
In summary, the Fudan University team’s discovery of an absolute quantification method for aging-associated IgG glycans, coupled with their integrative glycomic-transcriptomic framework and promising preliminary therapeutic results, heralds a new era in aging biomarker science and anti-aging therapy development. Their work not only enriches our comprehension of immune system aging but also lays a robust foundation for clinically actionable tools to measure, monitor, and potentially reverse aspects of biological aging.
Subject of Research: Aging-associated IgG N-glycans and biological age prediction using glycomics and transcriptomics.
Article Title: Absolute Quantification of Aging-Associated Glycans in IgG for Biological Age Prediction: Insights from Glycomics and Transcriptomics
News Publication Date: 17-Feb-2026
Web References:
https://doi.org/10.1016/j.eng.2025.07.042
https://www.sciencedirect.com/journal/engineering
Image Credits: Huijuan Zhao, Jiteng Fan et al.
Keywords: Biological aging, IgG N-glycans, glycomics, transcriptomics, absolute quantification, abGlycoAge, caloric restriction, glycoengineering, aging biomarkers, immune aging, RNA sequencing, glycan biomarkers
